Statistics from Altmetric.com
Respiratory failure is the most frequent cause of death in people with motor neuron disease (MND). Vital capacity and maximal inspiratory and expiratory mouth pressures are the methods most commonly used to assess respiratory muscle impairment. Forced vital capacity (FVC) at diagnosis, and the rate of decline, are predictors of survival. An FVC of <50% predicted is proposed by the National Institute of Clinical Excellence (NICE, UK) as an indication of the need for evaluation for non-invasive ventilation.1
For many patients with MND who have facial or bulbar muscle weakness, standard spirometry with a mouthpiece or tube is inaccurate due to mouth leaks as they are unable to effectively seal their lips around the tube/mouthpiece. Sniff nasal inspiratory pressure (SNIP), and maximal inspiratory mouth pressure (PiMax) may be preferable, but are less widely available and not always successful.2 Mask spirometry has been used but not validated in MND2 and in healthy volunteers, tube spirometry gives greater values than a mask.3 We compared mask and tube interfaces for spirometry in subjects with MND.
Consecutive patients were approached in our MND clinic. Exclusions included continuous ventilator dependence, tracheostomy and standard contraindications for spirometry. Bulbar involvement was quantified using the first three questions of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (b ALSFRS r score) and a score <9/12 defined important bulbar symptoms. FVC was measured with a calibrated hand-held spirometer via a tube or a face mask (Leardal, child No.4) in randomised order. PiMax and SNIP were also recorded by trained technicians (methodology explained in greater detail in on-line supplement).
Of 73 subjects approached, four declined consent, nine were excluded and 60, (36 men), mean age 64.7 (SD 10.5) years, were recruited. The mean b ALSFRS r score was 7.8 (SD 3.3) and half the subjects scored <9. The mask was preferred by 44 subjects. McNemar's test was used to compare the number of patients who were able to provide spirometry results with each interface. Successful measurement was achieved for mask spirometry in all 60, tube spirometry 54 (McNemar p<0.001), SNIP 51 and PiMax just 45 subjects. Compared with tube spirometry, the mask gave significantly greater values in those who managed both techniques (figure 1A). The difference was most marked at low volumes (figure 1B), and in people with bulbar symptoms (figure 1C). The six patients who could not record anything with tube spirometry were measured to have a mean FVC of 1.45 (SD 0.68) litres with the mask.
Respiratory muscle strength is a key prognostic factor in MND, and survival is measured in weeks when patients develop ventilatory failure.4 NICE guidelines recommend follow-up every 3 months, but a balance is needed between frequent disruptive clinic visits, and the risk of missing the opportunity to start NIV, which may improve survival and quality of life.4 It is possible that if the measured FVC is artefactually low, patients may be started prematurely on NIV. In Duchenne's Muscular Dystrophy this was shown to be associated with an adverse outcome.5 There are no data for MND, but it would seem to be at least a waste of a resource, and could negatively impact the patient's quality of life. In this study, regression models (figure 1B) showed that predicted mask spirometry measurements of FVC are higher for FVC <3 L, and in patients with moderate to severe bulbar involvement. Mask spirometry was achieved by more subjects than tube spirometry, SNIP or PiMax. Further studies to identify whether mask spirometry has better predictive power for time to ventilatory failure and need for NIV are justified.
We would like to thank the Research & Development Department at Papworth Hospital NHS Trust for arranging the randomisation sequences for mask and tube spirometry. We are grateful to all subjects who took part in this study.
Review history and Supplementary material
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online Supplement 1
All authors had full access to all the data in the study, and take full responsibility for the integrity of the data and the accuracy of the data analysis.
Contributors SB, MD and IS designed the study and obtained ethical approval. LS completed the statistical analysis and generated the figures. SB, MD and IS co-wrote the manuscript. All authors approved the final version.
Funding The research project was funded by a project grant from the Research & Development Department, Papworth Hospital NHS Trust. LS was supported by the Medical Research Council (Unit Programme number U015232027).
Competing interests None.
Patient Consent Obtained.
Ethics approval The study was conducted with approval of the Cambridgeshire III Research Ethics Committee (REC ref. no: 10/H0306/9).
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.